.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The AMPLE randomized clinical trial compared an indwelling pleural catheter with talc pleurodesis in patients with symptomatic malignant pleural effusion. The primary question was whether the catheter strategy could reduce the total number of days spent in hospital over the remaining lifespan. Patients allocated to an indwelling catheter spent fewer days in hospital overall, with much of the difference coming from fewer effusion-related hospitalization days. Both approaches are established ways of managing symptomatic malignant pleural effusion, so the trial is best understood as evidence for choosing the strategy that fits the patient rather than identifying one universal winner. Factors such as expandable versus trapped lung, expected prognosis, home support, procedural burden and patient preference all matter. This aligns with the NAPCON pleural-disease session and its emphasis on practical escalation and individualized management. The trial is also relevant to palliative care because the outcome of interest was not simply pleural fluid control, but how treatment affected hospital use during advanced disease. For HCPs, the paper supports discussing outpatient drainage options as part of goal-concordant care when appropriate.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The AMPLE randomized clinical trial compared an indwelling pleural catheter with talc pleurodesis in patients with symptomatic malignant pleural effusion. The primary question was whether the catheter strategy could reduce the total number of days spent in hospital over the remaining lifespan. Patients allocated to an indwelling catheter spent fewer days in hospital overall, with much of the difference coming from fewer effusion-related hospitalization days. Both approaches are established ways of managing symptomatic malignant pleural effusion, so the trial is best understood as evidence for choosing the strategy that fits the patient rather than identifying one universal winner. Factors such as expandable versus trapped lung, expected prognosis, home support, procedural burden and patient preference all matter. This aligns with the NAPCON pleural-disease session and its emphasis on practical escalation and individualized management. The trial is also relevant to palliative care because the outcome of interest was not simply pleural fluid control, but how treatment affected hospital use during advanced disease. For HCPs, the paper supports discussing outpatient drainage options as part of goal-concordant care when appropriate.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
